Trial Summary:

This is not an interventional study but a feasibility study measuring patient reported outcomes (PROs) in the evaluation of side effects and toxicities from steroid use in patients with brain tumours or brain metastases or advanced cancer. A multicentre cohort study with patient (including PRO measures), caregiver and clinician measures. Data will inform the baseline measures for a clinical study that will investigate whether acetazolomide, a steroid sparing agent can reduce the need for steroids and therefore reduce the side effects associated with steroid use.

Supported By:

COGNO; NHMRC CTC

Eligibility:

Recurrent and/or progressive HGG patients who require recommencement of dexamethasone or dose increase due to progressive raised ICP regardless of aetiology.

Registration ID:

ACTRN12611000378921

Participation:

Australia

Australian Lead Group:

COGNO

Status:

Closed

Activation Date:

5/07/2011

Chairs:

Dr Meera Agar

Contact:

seed.study@sydney.edu.au